MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03310cam a22004097i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
12744405 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-NcFUE |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20201208130507.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
020417s2002 enka b 001 0 eng d |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2002280285 |
| 015 ## - NATIONAL BIBLIOGRAPHY NUMBER |
|---|
| National bibliography number |
GBA2-Y9890 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9788126547890 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Cancelled/invalid ISBN |
0471496367 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Cancelled/invalid ISBN |
0471496375 (PBK.) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)ocm48930503 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
UKM |
| Transcribing agency |
UKM |
| Modifying agency |
DLC |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
lccopycat |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RS403 |
| Item number |
.B57 2002 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.19 |
| Edition number |
22 |
| Item number |
B.C.P |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Bladon, Christine M. |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Pharmaceutical chemistry : |
| Remainder of title |
therapeutic aspects of biomacromolecules / |
| Statement of responsibility, etc |
Christine M. Bladon. |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
Chichester : |
| Name of publisher, distributor, etc |
Wiley, |
| Date of publication, distribution, etc |
[2002] |
| 264 #3 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
Chichester : |
| Name of publisher, distributor, etc |
Wiley, |
| Date of publication, distribution, etc |
2014 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xii, 221 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Title page verso: First Printing 2002 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Introduction -- Overview -- Endocrine disorders -- Severe combined immunodeficiency disorders -- Biomacromolecules in the Treatment of Human Disease -- Endogenous Peptides and Proteins -- Overview -- Isolation from Natural Tissues and Fluids II -- Synthesis and Semi-Synthesis -- Peptide synthesis -- Gene Cloning -- Growth hormone -- Transgenic Procedures -- Examples of Direct Replacement Strategy -- Insulin -- The fibrin and fibrinolytic cascades -- Modification of Endogenous Peptides and Protcins -- Overview -- Peptide Mimetics -- Mimetics based on luteinizing hormone-releasing hormone -- Mimetics based on somatostatin -- Chemical Modification of Proteins -- Immunoassays --Modification with synthetic polymers -- Modification of enzyme active sites -- Protein Engineering -- Site-directed mutagenesis -- Chimeric toxins -- Chimeric and humanized antibodies -- The single-chain Fv -- Phage display -- The Immune System Overview -- The Antibody-Mediated Response -- Polyclonal antibodies -- Monoclonal antibodies -- Vaccines -- Hepatitis B vaccine -- Approaches to an HIV vaccine -- The Cell-Mediated Immune Response -- Immunoenhancement II -- Immunosuppression -- Cancer Immunotherapy -- Antibody-mediated immunotherapy -- T-cell-mediated immunotherapy -- Oligonucleotides -- Overview -- Gene Therapy -- Introduction -- Ex vio gene delivery -- Clinical applications -- Antisense Therapy -- Introduction -- Development of an antisense oligonucieotide -- Clinical studies IST -- Oligosaccharides -- Overview -- Oligosaccharide Synthesis -- Heparin -- Glycoproteins -- Blood group oligosaccharides -- Polysaccharide Bacterial Vaccines -- Approaches to Carbohydrate-Based Cancer Vaccines -- Appendix -- A.1 Amino Acids and Peprides A.LI Abbeeviations and structural representations -- Secondary structures -- A.2 Oligonocleotides. DNA and RNA -- Carbohydrates -- index. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmaceutical chemistry. |
| 856 42 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
Publisher description |
| Uniform Resource Identifier |
<a href="http://www.loc.gov/catdir/description/wiley035/2002280285.html">http://www.loc.gov/catdir/description/wiley035/2002280285.html</a> |
| 856 41 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
Table of contents |
| Uniform Resource Identifier |
<a href="http://www.loc.gov/catdir/toc/wiley022/2002280285.html">http://www.loc.gov/catdir/toc/wiley022/2002280285.html</a> |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
7 |
| b |
cbc |
| c |
copycat |
| d |
2 |
| e |
ncip |
| f |
20 |
| g |
y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Books |